STOCK TITAN

Landos Biopharma, Inc. - $LABP STOCK NEWS

Welcome to our dedicated page for Landos Biopharma news (Ticker: $LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma stock.

Landos Biopharma, Inc. (NASDAQ: LABP) is a clinical-stage biopharmaceutical company dedicated to developing novel, oral treatments for patients suffering from autoimmune diseases. The company's mission is to create therapies that are safer, more effective, and less disruptive for patients, addressing significant gaps in current treatment options.

Landos is particularly focused on developing therapies for inflammatory bowel disease (IBD) and its two main forms: Crohn’s disease and ulcerative colitis (UC). The company's lead asset, NX-13, is a first-in-class, oral NLRX1 agonist designed to treat UC. NX-13 has shown promising preclinical results and is currently undergoing a Phase 2 clinical trial (NEXUS) aimed at proving its efficacy and safety. The NEXUS trial, which began in the second quarter of 2023, is actively recruiting and screening patients, with top-line results expected in the fourth quarter of 2024.

Financially, Landos reported cash, cash equivalents, and marketable securities of $44.7 million as of June 30, 2023. This cash reserve is expected to support the company's operations through the first half of 2025. The company’s research and development expenses have decreased to $2.5 million in Q2 2023, primarily due to the winding down of earlier clinical activities and the initiation of the NEXUS trial.

On the corporate front, Landos has formed significant partnerships to enhance its research capabilities. A notable collaboration with KU Leuven aims to explore the effects of NX-13 on UC patient-derived organoid models, providing deeper insights into its mechanism of action and potential clinical benefits.

In a strategic move, Landos announced that it will be acquired by AbbVie Inc. (NYSE: ABBV) for $20.42 per share in cash, plus contingent value rights potentially worth up to $11.14 per share. This acquisition underscores the value and potential of NX-13 and highlights the strength of Landos' research and development efforts. The transaction is expected to close in the second quarter of 2024, subject to customary conditions.

For more information about Landos Biopharma and its groundbreaking work in autoimmune disease treatment, visit www.landosbiopharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.02%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
management

FAQ

What is Landos Biopharma, Inc.?

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral therapies for autoimmune diseases, particularly inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.

What is NX-13?

NX-13 is Landos Biopharma's lead drug candidate. It is a first-in-class, oral NLRX1 agonist designed to treat ulcerative colitis. NX-13 is currently in a Phase 2 clinical trial.

What is the NEXUS trial?

The NEXUS trial is a Phase 2 clinical trial for NX-13, aimed at proving its efficacy and safety in treating moderate-to-severe ulcerative colitis. The trial began in the second quarter of 2023 and is expected to have top-line results by the fourth quarter of 2024.

How is Landos Biopharma funded?

As of June 30, 2023, Landos Biopharma reported $44.7 million in cash, cash equivalents, and marketable securities, which are expected to fund its operations through the first half of 2025.

Has Landos Biopharma formed any significant partnerships?

Yes, Landos has partnered with KU Leuven to explore the effects of NX-13 on UC patient-derived organoid models, providing deeper insights into its mechanism of action and potential clinical benefits.

What are the recent financial results for Landos Biopharma?

For the second quarter of 2023, Landos reported research and development expenses of $2.5 million and general and administrative expenses of $2.0 million, reflecting decreases from the same period in 2022.

Is Landos Biopharma being acquired?

Yes, Landos Biopharma will be acquired by AbbVie Inc. for $20.42 per share in cash, plus contingent value rights potentially worth up to $11.14 per share. The transaction is expected to close in the second quarter of 2024.

How can I get more information about Landos Biopharma?

More information about Landos Biopharma and their work can be found on their official website at www.landosbiopharma.com.

What drives the research at Landos Biopharma?

Landos Biopharma is driven by the goal of offering safer, more effective, and less disruptive treatment options for patients with autoimmune diseases, addressing the unmet clinical needs in this area.

What are some recent developments for Landos Biopharma?

Recent developments include the advancement of the NX-13 Phase 2 clinical trial, significant financial updates, and the strategic acquisition by AbbVie Inc.

Landos Biopharma, Inc.

Nasdaq:LABP

LABP Rankings

LABP Stock Data

71.68M
1.33M
9.89%
52.04%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BLACKSBURG